In the present study we demonstrate for the first time that the novel anti-VEGFR-1 mAb D16F7, which diminishes receptor activation by VEGF-A and PlGF, inhibits chemotaxis and ECM invasion of human GBM and patient-derived GSC lines. This evidence concerns the gene FLT1 and glioblastoma.